DHHealthcare · Health Information ServicesThe 7 Wall Street analysts covering Definitive Healthcare Corp. hold a median 12-month price target of $1.25 — +2.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Definitive Healthcare Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (19): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | Morgan Stanley | Maintains | Equal-Weight | $2.50 → $1.50 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | $3.50 → $0.70 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 30 Mar 2026 | Barclays | Maintains | Underweight | — |
| 27 Feb 2026 | Canaccord Genuity | Maintains | Hold | — |
| 27 Feb 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 9 Dec 2025 | Barclays | Maintains | Underweight | — |
| 10 Nov 2025 | Canaccord Genuity | Maintains | Hold | — |
| 8 Aug 2025 | Stifel | Maintains | Buy | — |
| 12 May 2025 | Goldman Sachs | Maintains | Neutral | — |
| 4 Mar 2025 | Goldman Sachs | Maintains | Neutral | — |
| 3 Mar 2025 | Barclays | Maintains | Underweight | — |
| 16 Jan 2025 | Needham | Reiterates | Hold | — |
| 13 Jan 2025 | Barclays | Downgrade | Underweight | — |
| 20 Dec 2024 | Stephens & Co. | Initiates | Equal-Weight | — |
| 8 Nov 2024 | Needham | Reiterates | Hold | — |
| 17 Sept 2024 | BTIG | Initiates | Buy | — |
| 9 Aug 2024 | Deutsche Bank | Maintains | Hold | — |
| 7 Aug 2024 | Baird | Maintains | Neutral | — |
| 7 Aug 2024 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Definitive Healthcare Corp. returned −55.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 80% of US stocks
Cheaper than 74% of US stocks
Cheaper than 54% of US stocks
Higher than 16% of US stocks
Higher than 27% of US stocks
Higher than 86% of US stocks
Higher than 25% of US stocks
Higher than 8% of US stocks
Higher than 16% of US stocks
Higher than 37% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Definitive Healthcare Corp. has a market value of $124.9M and an enterprise value of $151.4M.
Revenue in the twelve months to 30 June 2026: $232.7M. The latest quarter shrank 9.1% year on year.
Net income over the same four quarters: −$234.7M, a −100.9% net margin.
Diluted earnings per share, trailing twelve months: $−1.60.
Free cash flow in the twelve months to 30 June 2026: $28.6M.
Definitive Healthcare Corp. spent $9.2M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −0.9×; forward P/E: 6.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Definitive Healthcare Corp. employs 678 people — $343K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Definitive Healthcare Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Definitive Healthcare announced that it hired a Head of AI and promoted a new Chief Product Officer to support AI-powered initiatives across the company.
Why it matters — The appointments signal changes in leadership focused on DH’s AI and product initiatives.
Definitive Healthcare has joined the Network Advertising Initiative, an industry body focused on data privacy compliance, aligning itself with other leaders in the sector to reinforce its commitment to the highest standards of health data safety in healthcare marketing.
Why it matters — This membership signals Definitive Healthcare's proactive focus on data privacy compliance, an area closely watched by clients and regulators in the healthcare data space.
Definitive Healthcare Corp. announced that a special committee of its board has received a non-binding indication of interest from Advent International to acquire all outstanding shares of Class A common stock and Definitive OpCo Units it does not already own, at an all-cash price of $1.02 per share, dated September 1, 2026.
Why it matters — A DH watcher would track this because a going-private proposal for all outstanding stock and units is a significant corporate transaction that could determine the company's future ownership and structure.
Definitive Healthcare Corp. announced that its Board of Directors has appointed Clay Ritchey as the Company's next Chief Executive Officer and as a member of the Board of Directors, effective September 8, 2026.
Why it matters — A new CEO appointment signals a leadership transition at Definitive Healthcare that DH watchers will want to track as it takes effect in September 2026.
Definitive Healthcare Corp. (DH) held its Q2 2026 earnings call, and the full transcript of that call has been published by Seeking Alpha. The transcript covers the company's second-quarter fiscal 2026 results discussion.
Why it matters — DH watchers would care because the earnings call transcript provides the full management commentary on the company's Q2 2026 performance and outlook.
The 7 Wall Street analysts covering Definitive Healthcare Corp. have a median 12-month price target of $1.25, with estimates ranging from $1 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Definitive Healthcare Corp., 1 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Definitive Healthcare Corp. 83 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Definitive Healthcare Corp. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +2.0% from the last close, and Ticker Nerd's factor model ranks Definitive Healthcare Corp. 83 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Definitive Healthcare Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3 over the next 12 months.
Definitive Healthcare Corp. returned -55.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Definitive Healthcare Corp. Class A Common Stock represents ownership in Definitive Healthcare Corp., a healthcare commercial intelligence company focused on software and data solutions for the healthcare industry.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "Definitive Healthcare announces executive appointments to bolster AI-powered initiatives across the company". Definitive Healthcare announced that it hired a Head of AI and promoted a new Chief Product Officer to support AI-powered initiatives across the company.
Definitive Healthcare Corp. Class A Common Stock represents ownership in Definitive Healthcare Corp., a healthcare commercial intelligence company focused on software and data solutions for the healthcare industry. Definitive Healthcare provides a cloud-based platform that organizes and analyzes information on healthcare providers, organizations, and related activities to support sales, marketing, clinical research, product development, and strategic planning. Its services are used by biopharmaceutical companies, medical device makers, healthcare technology firms, providers, and other organizations that operate across the healthcare ecosystem. The company is headquartered in Framingham, Massachusetts, and its Class A common stock is part of the public equity market used by investors to gain exposure to a specialized healthcare software and analytics business.
CEO Mr. Clay Ritchey · 678 employees · United States · https://www.definitivehc.com
